MARKET

BEAT

BEAT

BioTelemetry
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.89
-1.10
-2.45%
After Hours: 43.51 -0.38 -0.87% 17:04 10/19 EDT
OPEN
45.07
PREV CLOSE
44.99
HIGH
45.60
LOW
43.89
VOLUME
221.96K
TURNOVER
--
52 WEEK HIGH
55.85
52 WEEK LOW
27.35
MARKET CAP
1.50B
P/E (TTM)
83.08
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
G Medical Innovations Ups IPO In Second Try
G Medical Innovations is seeking $30 million in a U.S. IPO.The firm sells cardiac monitoring products and services.GMVD has suffered contracting revenue, has an uncertain future in a continuing Covid-19 environment and the IPO is excessively priced, so I'll pass.
Seekingalpha · 3d ago
BioTelemetry (BEAT) Looks Good: Stock Adds 7.7% in Session
BioTelemetry (BEAT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zacks · 09/14 13:27
BioTelemetry cheers Needham's Buy initiation
Needham initiated BioTelemtry ([[BEAT]] +6.0%) with a Buy rating, price target of $52, indicating upside of 33% from current levels.Analyst David Saxon says that sales mix shift in Healthcare, the
Seekingalpha · 09/11 17:34
Calculating The Fair Value Of BioTelemetry, Inc. (NASDAQ:BEAT)
Today we will run through one way of estimating the intrinsic value of BioTelemetry, Inc. (NASDAQ:BEAT) by estimating...
Simply Wall St. · 09/07 12:20
Benzinga's Top Upgrades, Downgrades For September 2, 2020
Upgrades * For Zillow Group Inc (NASDAQ: ZG), Deutsche Bank upgraded the previous rating of Hold to the current rating Buy. In the second quarter, Zillow Gr showed an EPS of $0.41, compared to $0.14 from the year-ago quarter. At the moment, the stock has a 52-week-high of $88.82 and a 52-week-low of
Benzinga · 09/02 15:20
BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates
BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 23:50
BioTelemetry inks sales agent agreement with Boston Scientific
Boston Scientific (BSX -3.1%) has announced a sales agent agreement with BioTelemetry (BEAT +6.1%), for BSX's LUX-Dx Insertable Cardiac Monitor (ICM) Syste
seekingalpha · 07/30 20:15
BioTelemetry Q2 EPS $0.35 Beats $0.16 Estimate, Sales $89.41M Miss $89.52M Estimate
BioTelemetry (NASDAQ:BEAT) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.16 by 118.75 percent. This is a 33.96 percent decrease over earnings of $0.53 per share from the
Benzinga · 07/30 20:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BEAT. Analyze the recent business situations of BioTelemetry through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BEAT stock price target is 54.33 with a high estimate of 61.00 and a low estimate of 43.00.
EPS
Institutional Holdings
Institutions: 330
Institutional Holdings: 33.96M
% Owned: 99.35%
Shares Outstanding: 34.19M
TypeInstitutionsShares
Increased
73
1.12M
New
57
-235.59K
Decreased
81
1.44M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-1.14%
Healthcare Providers & Services
-1.54%
Key Executives
Chairman/Independent Director
Kirk Gorman
Chief Executive Officer/President/Director
Joseph Capper
Chief Financial Officer/Executive Vice President/Chief Administrative Officer
Heather Getz
Corporate Executive
Fred Broadway
Senior Vice President
Daniel Wisniewski
Chief Technology Officer
Andrei Stoica
Other
Manish Wadhwa
Director
Stephan Rietiker
Independent Director
Anthony Conti
Independent Director
Laura Dietch
Independent Director
Joseph Frick
Independent Director
Colin Hill
Independent Director
Tiffany Olson
Independent Director
Rebecca Rimel
Independent Director
Robert Rubin
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BEAT
BioTelemetry, Inc. provides monitoring services and digital population health management in a healthcare setting, medical device manufacturing and centralized laboratory services for clinical research. The Company operates in three segments: Healthcare, Technology and Research. The Healthcare segment, operating as CardioNet, LLC and Heartcare Corporation of America, Inc., is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Research segment, operating as Cardiocore, LLC and VirtualScopics, Inc., is engaged in laboratory services that provide cardiac monitoring, imaging services, scientific consulting and data management services for drug, medical treatment and device trials. The Technology segment, operating as Braemar Manufacturing, LLC, Universal Medical, Inc. and BioTelemetry Belgium BVBA. and BioTelemetry Technology ApS, focuses on the manufacturing, engineering and development of noninvasive cardiac monitors for healthcare companies.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioTelemetry Inc stock information, including NASDAQ:BEAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BEAT stock methods without spending real money on the virtual paper trading platform.